# Lassonde Industries Inc. (LAS-A.TO) fundamentals

Data as of 2026-09-08. TSX, Canada. Sector: Consumer Defensive / Beverages. Price C$235.80, market value C$1.6 billion.

## Valuation
- **P/E (trailing): 10.4×** (5-yr avg 11.4×, 3-yr avg 10.4×). Lassonde Industries Inc. trades at 10.4× trailing earnings, close to its own five-year average of 11.4×. The Consumer Defensive median in the September 2026 study was 20.1×. Forward P/E is 8.9×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.28**. A PEG of 0.28 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 0.6×**. Each dollar of revenue is priced at 0.6×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 1.3×**. The shares trade at 1.3× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 6.3×**. Enterprise value is 6.3× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 14.2%** (5-yr avg 4.9%). Free cash flow equals 14.2% of the market value, above its five-year average of 4.9%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 9.6%**. The inverse of the P/E: 9.6% of the price is earned each year.

## Profitability
- **Gross margin: 29.0%**. Lassonde Industries Inc. keeps 29.0% of revenue after the direct cost of what it sells.
- **Operating margin: 8.7%**. 8.7% of revenue is left after running the business.
- **Net margin: 5.1%**. 5.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 13.1%**. 13.1% on shareholders' equity is solid.
- **Return on invested capital: 11.8%**. Return on all capital, debt included, is 11.8%.
- **Return on assets: 6.9%**. Each dollar of assets produces 6.9% of profit.

## Growth
- **Revenue growth (1 yr): 12.8%** (3-yr 10.9%/yr, 5-yr 8.2%/yr). Revenue grew 12.8% over the last year, against 8.2% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 31.1%** (3-yr 40.9%/yr, 5-yr 9.2%/yr). Earnings per share rose 31.1%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.44**. Debt is 0.44 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 1.5×**. It would take 1.5 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 7.5×**. Operating profit covers interest 7.5× over, a safe margin.
- **Current ratio: 1.75** (quick 0.64). Current assets cover the next year's liabilities 1.75 times.
- **Altman Z-score: 3.46**. A Z-score of 3.46 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 2.12%** (C$4.70 per share, trailing). Lassonde Industries Inc. yields 2.12%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 20%** (14% of free cash flow). 20% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 2**. 2 straight years of increases.
- **Dividend growth (5 yr): 11.6%/yr** (1-yr 10.0%). The dividend has compounded at 11.6% a year over five years, doubling roughly every 6 years at that pace.

## Price and momentum
- **Total return (1 yr): 13.1%** (YTD 8.0%, 3-mo 7.0%). The shares are up 13.1% over twelve months including dividends.
- **From 52-week high: -7.1%** (16.4% above the low). Trading 7% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 0.33** (volatility 34%). Beta of 0.33 against the S&P/TSX Composite: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LAS-A.TO · Page: https://foliofundamentals.com/stocks/las-a.to

Not investment advice.